Valencia Technologies, a medical device company that has created a tiny and inexpensive neurostimulator, announces the issuance of two additional patents by the US Patent Office.
The total number of patents issued to this clinical stage company is now nine.
Valencia’s invention is based on the discovery that constant stimulation is not required to modulate a nerve. If constant stimulation is not required, a radically small (about the size of a coin), fully implantable device can be developed and placed subcutaneously near any peripheral nerve. Valencia’s basic technology combines a number of ideas: a coin-sized, self-contained, implantable neurostimulator using low-duty cycle stimulation to effect a good.
The issuance of U.S. Patent Number 9,066,845 deepens the protection of the system by specifically addressing electrode configuration of a device contemplating the integration of the anodic and cathodic material within the body of the stimulator; that is, Valencia’s device does not contain lead wires.
While the first commercial application for the system is hypertension, the Valencia system is applicable to other chronic conditions.
Because of its size and shape, the tiny device can be implanted near target nerves making for a broad based commercial device.
Certain nerves, locations and electrical paradigms are identified by Valencia in its issued and pending patents. With newly issued U.S. Patent Number 9,078,801, Valencia obtains protection over the use of its system for treatment of erectile dysfunction. The device is implanted in the lower back, the target location for stimulation.
Reflecting on Valencia’s developing patent portfolio, CEO Jeff Greiner believes, "that we’ve invented the first coin-cell sized pacemaker that can be used to address several major chronic conditions including hypertension, depression, intractable pain, heart failure, Parkinson’s, and erectile dysfunction."
Furthermore, Greiner indicated that, "our issued patents reflect the novelty of our technology and minimally-invasive approach." Greiner says the device takes 20 minutes to implant for its hypertension application.
Valencia additionally received four allowances with expected issue dates between the end of July and the end of September. These allowances cover both technology of the novel device and the additional applications of dyslipidemia, obesity, and depression.